Literature DB >> 3390972

Peripheral blood monocyte/macrophages and serum tumor necrosis factor in Kawasaki disease.

S Furukawa1, T Matsubara, K Jujoh, K Yone, T Sugawara, K Sasai, H Kato, K Yabuta.   

Abstract

We analyzed the populations of peripheral blood monocyte/macrophages in 27 patients using a fluorescence-activated cell sorter, and investigated the possibility, in another 30 patients, that tumor necrosis factor (TNF) might be detectable in serum during the acute phase of Kawasaki disease (KD). Percentages of peripheral blood monocyte/macrophages among mononuclear cells and serum TNF levels were both seen to increase during the acute phase of the illness in patients with KD. The percentage of TNF positive cases in KD patients with coronary involvement was higher than that of patients without coronary involvement. These results suggest the possibility that immunological activation, accompanied by the secretion of TNF from monocyte/macrophages, is an important predisposing condition for the exacerbation of vascular damage in KD.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3390972     DOI: 10.1016/0090-1229(88)90088-8

Source DB:  PubMed          Journal:  Clin Immunol Immunopathol        ISSN: 0090-1229


  52 in total

1.  CD14+CD16+ monocyte subpopulation in Kawasaki disease.

Authors:  K Katayama; T Matsubara; M Fujiwara; M Koga; S Furukawa
Journal:  Clin Exp Immunol       Date:  2000-09       Impact factor: 4.330

2.  Th1 and Th2 cytokine production is suppressed at the level of transcriptional regulation in Kawasaki disease.

Authors:  J Kimura; H Takada; A Nomura; T Ohno; Y Mizuno; M Saito; K Kusuhara; T Hara
Journal:  Clin Exp Immunol       Date:  2004-08       Impact factor: 4.330

Review 3.  Anti-neutrophil cytoplasmic antibodies and anti-endothelial cell antibodies.

Authors:  M J Dillon; E J Tizard
Journal:  Pediatr Nephrol       Date:  1991-03       Impact factor: 3.714

4.  Study design and rationale to assess Doxycycline Efficacy in preventing coronary Artery Lesions in children with Kawasaki disease (DEAL trial) - A phase II clinical trial.

Authors:  Andras Bratincsak; Blair N Limm-Chan; Vivek R Nerurkar; Lauren L Ching; Venu D Reddy; Eunjung Lim; Ralph V Shohet; Marian E Melish
Journal:  Contemp Clin Trials       Date:  2017-12-05       Impact factor: 2.226

Review 5.  Intravenous immunoglobulin therapy in vasculitis: speculation or evidence?

Authors:  Peer Malte Aries; Bernhard Hellmich; Wolfgang Ludwig Gross
Journal:  Clin Rev Allergy Immunol       Date:  2005-12       Impact factor: 8.667

Review 6.  Facing the enigma of immunomodulatory effects of intravenous immunoglobulin.

Authors:  Tal Sapir; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2005-12       Impact factor: 8.667

7.  Polymorphisms in chemokine receptor genes and susceptibility to Kawasaki disease.

Authors:  W B Breunis; M H Biezeveld; J Geissler; I M Kuipers; J Lam; J Ottenkamp; A Hutchinson; R Welch; S J Chanock; T W Kuijpers
Journal:  Clin Exp Immunol       Date:  2007-08-02       Impact factor: 4.330

Review 8.  The immunoregulatory effects of IVIG in Kawasaki disease and other autoimmune diseases.

Authors:  D Y Leung
Journal:  Clin Rev Allergy       Date:  1992 Spring-Summer

Review 9.  Immunological profile of peripheral blood lymphocytes and monocytes/macrophages in Kawasaki disease.

Authors:  T Matsubara; T Ichiyama; S Furukawa
Journal:  Clin Exp Immunol       Date:  2005-09       Impact factor: 4.330

10.  Serum soluble CD4 and CD8 levels in Kawasaki disease.

Authors:  S Furukawa; T Matsubara; K Tsuji; T Motohashi; K Okumura; K Yabuta
Journal:  Clin Exp Immunol       Date:  1991-10       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.